Operating cash flow of $48.7M in Q1 2026 reversed to -$27.6M in Q3 2026 with free cash flow at -$27.7M, while a $836.3M net acquisition outflow and $60.0M in buybacks signal capital deployment outpacing recent cash generation.
Ligand Pharmaceuticals Incorporated (LGND) cash flow statement — 30-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Cash from Operations | 90.96M | 49.36M | 97.05M | 49.58M | 137.85M | 78.8M | 54.59M | -29.34M | 194.06M | 93.57M | 63M | 41.73M | 20.57M | 20.69M | 161K | -1.17M | -27.07M | -33.8M | -20.63M | -97.73M | -138.52M | 8.37M | 5.75M | 274K | -25.11M | -19.91M | -47.35M | -60.5M | -66.6M | -13.4M | -33.3M |
| Operating CF Margin % | - | 18.41% | 58.07% | 37.75% | 70.24% | 32.62% | 33.37% | -24.39% | 77.18% | 66.31% | 57.81% | 58.02% | 31.87% | 42.25% | 0.51% | -3.9% | -114.99% | -86.8% | -75.51% | -757.93% | -98.27% | 4.74% | 3.52% | 0.19% | -25.99% | -26.08% | -98.43% | -147.92% | -376.27% | -25.92% | -90.49% |
| Operating CF Growth % | 93.11% | -49.14% | 95.75% | -64.04% | 74.94% | 44.36% | 286.07% | -115.12% | 107.4% | 48.52% | 50.98% | 102.89% | -0.6% | 12750.93% | 113.74% | 95.67% | 19.92% | -63.88% | 78.9% | 29.45% | -1755.96% | 45.38% | 2000% | 101.09% | -26.15% | 57.96% | 21.73% | 9.16% | -397.01% | 59.76% | 12.14% |
| Net Income | 51.46M | 124.45M | -4.03M | 52.15M | -33.36M | 57.14M | -2.98M | 629.3M | 143.32M | 12.56M | -2.37M | 254.93M | 10.89M | 8.83M | -2.67M | 10.17M | -12.79M | -8.34M | -98.11M | 281.69M | -31.74M | -36.4M | -45.14M | -37.46M | -32.6M | -42.99M | -59.28M | -74.7M | -117.9M | -100.2M | -37.3M |
| Depreciation & Amortization | 36.38M | 33.77M | 35.24M | 36.52M | 43.39M | 50.95M | 27.97M | 43.73M | 14.72M | 11.71M | 11.29M | 2.63M | 2.66M | 2.66M | 2.73M | 2.79M | 2.21M | 3.13M | 1.05M | 2.62M | 16.22M | 18.71M | 15.28M | 14.28M | 10.47M | 6.57M | 6.97M | 7.4M | 7.7M | 9.8M | 9.4M |
| Stock-Based Compensation | 56.7M | 0 | 41.09M | 25.74M | 60.28M | 38.78M | 30.73M | 24.52M | 20.85M | 24.91M | 18.89M | 12.46M | 11.27M | 5.67M | 4.07M | 3.35M | 2.33M | 3.37M | -537K | 7.58M | 5.34M | 107K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | -8.35M | 22.68M | -15.8M | 11.7M | 20.72M | -8.62M | -19.05M | 74.83M | 29.74M | 44.52M | 10.7M | -219.61M | 410K | 374K | -1.2M | -13.26M | 5.99M | -22.8M | -1.36M | -5.79M | -9.66M | -107K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -5.82M | -118.89M | 21.2M | -42.13M | -18.87M | -7.29M | 28M | -797.5M | 24.29M | 11.3M | 35.11M | -9.49M | 6.29M | 3.86M | 13K | 1.65M | -68K | 9.17M | 79.64M | -327.99M | -36.01M | -578K | -5.57M | 8.59M | 3.83M | 16.56M | -2.79M | 15.5M | 45.1M | 64.9M | -1.4M |
| Working Capital Changes | -39.41M | -12.66M | 19.36M | -34.4M | 65.68M | -52.16M | -10.06M | -4.21M | -38.85M | -11.44M | -10.62M | 821K | -10.95M | -702K | -2.77M | -5.88M | -24.74M | -18.33M | -1.31M | -55.83M | -82.66M | 26.64M | 41.19M | 14.86M | -6.81M | -42K | 7.74M | -8.7M | -1.5M | 12.1M | -4M |
| Change in Receivables | -25.8M | -21.74M | -6.46M | -2.6M | 55.32M | -28.62M | -26.06M | 25.46M | -29.54M | -8.36M | -8.53M | 6.49M | -10.41M | 2.37M | 1.52M | -3.92M | -375K | -618K | 0 | 11.54M | 9.43M | 0 | -11.95M | -6.88M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | -2.61M | 4.99M | 9.62M | -10.87M | 12.06M | -427K | -17.8M | -2.06M | -2.56M | -843K | -244K | -401K | 4.37M | 646K | 1.03M | 1.11M | -3.93M | -448K | 0 | 930K | 1.58M | -3.43M | -3.29M | -3.42M | -1.08M | 1.9M | 81K | 400K | -2.9M | 0 | 0 |
| Change in Payables | 8.91M | 5.88M | 0 | -4.7M | -3.34M | -1.17M | -1.25M | -18.05M | -4.54M | -1.71M | -2.37M | -4.03M | -3.15M | -2.76M | -4.8M | -11.57M | -13.45M | -10.99M | 0 | -51.89M | -27.64M | 0 | 9.75M | 24.52M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | -669.33M | -377.32M | -143.66M | -11.68M | 163.62M | 30.52M | 231.65M | 466.92M | -423.27M | -84.18M | -143.19M | -112.86M | -2.03M | -4.97M | 1.26M | -25.13M | 14.54M | 24.77M | -24.42M | 343.84M | 196.87M | -33.72M | 19.61M | -24.62M | -105.25M | -4.17M | 14.65M | -24.9M | -28.6M | 4.3M | 7.5M |
| Capital Expenditures | -3.04M | -11.31M | -1.82M | -3.52M | -17.92M | -8.76M | -4.46M | -2.55M | -11.89M | -7.15M | -28.32M | -10.86M | -4.5M | -4.94M | -8.64M | -78K | -70K | -522K | -495K | -440K | -1.78M | -35.6M | -3.6M | -2.78M | -3.16M | -1.97M | -1.08M | -39.5M | -2.4M | -4.3M | -400K |
| CapEx % of Revenue | 1.2% | 4.22% | 1.09% | 2.68% | 9.13% | 3.63% | 2.73% | 2.12% | 4.73% | 5.07% | 25.99% | 15.11% | 6.97% | 10.08% | 27.54% | 0.26% | 0.3% | 1.34% | 1.81% | 3.41% | 1.26% | 20.16% | 2.2% | 1.97% | 3.27% | 2.59% | 2.26% | 96.58% | 13.56% | 8.32% | 1.09% |
| Acquisitions | -836.33M | -8.09M | -172.19M | -25.65M | -750K | 494K | -383.32M | -12.84M | -5.86M | -26.65M | -94.2M | -9.25M | -3.49M | -989K | 0 | -32.02M | -2.83M | 9.8M | 4.13M | 310.14M | 183.33M | 0 | 0 | 0 | 0 | 0 | -200K | 0 | 100K | 100K | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 9.88M | -4.34M | -12.89M | -49.91M | -868K | -1.22M | 3.26M | 808.13M | 3.91M | 7.25M | 300K | -15.99M | 130K | -37K | -93K | -2.38M | -1.01M | 539K | 8.29M | 39.59M | 8.14M | 181K | -131K | -3.86M | -106.2M | 281K | 11.88M | -5.2M | -9.3M | -16.8M | -200K |
| Cash from Financing | 544.69M | 428.22M | 97.14M | -59.95M | -275.99M | -137.76M | -310.55M | -485.17M | 328.58M | -7.52M | 1.51M | 8.36M | 130.03M | -16.46M | 3.92M | 30M | -159K | -3.69M | -3.01M | -327.7M | 33.3M | -201K | 7.92M | 40.95M | 152.04M | 35.59M | 12.03M | 82.5M | 65.8M | 36.5M | 44.7M |
| Debt Issued (Net) | 488.78M | 338.11M | -25K | -76.9M | -260.8M | -146.01M | -231.76M | -27.32M | 532.33M | 0 | 0 | 0 | 235.63M | -19.59M | -2.5M | 30M | -91K | -3.92M | -1.53M | -2.17M | 24.4M | -1.1M | 1.49M | -1.35M | 99.38M | 7.96M | -2.75M | 59.6M | 27M | -700K | 2.4M |
| Equity Issued (Net) | 85.28M | 99.89M | 37.14M | 22.45M | 3.23M | 15.32M | -78M | -457.47M | -126.63M | -1.97M | 2.51M | -489K | -67.95M | 3.13M | 5.44M | -55K | -68K | 228K | -1.48M | -35.22M | 9.05M | 930K | 6.62M | 33.58M | 70.75M | 28.58M | 14.19M | 22.3M | 38.3M | 36.7M | 39M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -252.56M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -60M | -15M | 0 | 0 | 0 | -18.45M | -78M | -453.05M | -122.87M | -1.97M | -3.9M | -489K | -67.95M | 0 | 0 | -55K | -91K | 0 | -1.61M | -39.61M | 0 | 0 | 0 | -15.87M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -29.36M | -9.77M | 60.03M | -5.5M | -18.42M | -7.07M | -789K | -383K | -77.11M | -5.56M | -999K | 8.85M | -37.66M | 0 | 979K | 54K | 0 | 0 | 0 | -37.56M | -153K | -35K | -189K | 8.72M | -18.09M | -936K | 577K | 600K | 500K | 500K | 3.3M |
| Net Change in Cash | -35.98M | 102.62M | 49.35M | -22.05M | 25.48M | -28.44M | -24.31M | -47.51M | 99.16M | 1.87M | -78.68M | -62.77M | 148.56M | -742K | 5.34M | 3.69M | -12.69M | -12.72M | -48.06M | -81.59M | 91.64M | -25.55M | 33.28M | 16.61M | 21.68M | 11.52M | -20.68M | -2.9M | -29.5M | 27.4M | 18.9M |
| Free Cash Flow | 90.56M | 48.91M | 77.41M | -4.27M | 119.93M | 70.04M | 50.13M | -31.89M | 182.17M | 86.41M | 34.68M | 30.86M | 16.07M | 15.75M | -8.48M | -1.25M | -27.14M | -34.32M | -21.12M | -98.17M | -140.3M | -27.23M | 2.15M | -2.51M | -28.27M | -21.88M | -48.44M | -100M | -69M | -17.7M | -33.7M |
| FCF Margin % | 35.68% | 18.24% | 46.31% | -3.25% | 61.11% | 29% | 30.65% | -26.51% | 72.45% | 61.24% | 31.82% | 42.92% | 24.9% | 32.17% | -27.03% | -4.16% | -115.29% | -88.14% | -77.32% | -761.34% | -99.53% | -15.42% | 1.31% | -1.78% | -29.26% | -28.66% | -100.69% | -244.5% | -389.83% | -34.24% | -91.58% |
| FCF Growth % | 195.1% | -36.82% | 1911.96% | -103.56% | 71.23% | 39.72% | 257.2% | -117.5% | 110.81% | 149.18% | 12.36% | 92.1% | 1.99% | 285.7% | -578.64% | 95.39% | 20.94% | -62.51% | 78.49% | 30.03% | -415.24% | -1366.56% | 185.69% | 91.13% | -29.22% | 54.83% | 51.56% | -44.93% | -289.83% | 47.48% | 11.55% |
| FCF per Share | 4.54 | 2.41 | 4.23 | -0.24 | 7.11 | 4.06 | 3.10 | -1.61 | 7.57 | 3.68 | 1.66 | 1.45 | 0.75 | 0.76 | -0.43 | -0.06 | -1.38 | -1.82 | -1.33 | -6.00 | -10.44 | -2.21 | 0.18 | -0.21 | -2.45 | -2.21 | -5.22 | -12.73 | -10.25 | -3.21 | -7.03 |
| FCF Conversion (FCF/Net Income) | 1.76x | 0.40x | -24.07x | 0.95x | -4.13x | 1.38x | -18.29x | -0.05x | 1.35x | 7.45x | -38.51x | 0.16x | 1.71x | 1.81x | -0.31x | -0.12x | 2.16x | 17.35x | 0.21x | -0.35x | 4.36x | -0.23x | -0.13x | -0.01x | 0.77x | 0.46x | 0.65x | 0.81x | 0.56x | 0.13x | 0.89x |
| Interest Paid | 2.34M | 0 | 263K | 288K | 1.43M | 3.03M | 4.46M | 5.83M | 1.51M | 1.84M | 1.84M | 1.82M | 494K | 1.82M | 0 | 2.46M | 58K | 270K | 229K | 1.51M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 4.67M | 0 | 19.21M | 8.77M | 11.64M | 3.72M | 2.13M | 103.82M | 341K | 157K | 38K | 28K | 18K | 26K | 0 | 39K | 28K | 14K | 140K | 8.37M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying LGND stock.
Ligand Pharmaceuticals Incorporated (LGND) generated $49.4M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Ligand Pharmaceuticals Incorporated (LGND) generated $48.9M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Ligand Pharmaceuticals Incorporated (LGND) spent $11.3M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Ligand Pharmaceuticals Incorporated (LGND) spent $15.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.
Key Metrics
Top Statement Risk
Volatile operating cash conversion
Metrics are mathematically derived from official filings.
Net Income Poorly Converts to Operating Cash
Based on reported quarterly figures, LGND's operating cash flow to net income ratio swung from -3.65 in Q1 2026 to 3.26 in Q2 2025, indicating earnings quality that is highly unstable and not reliably backed by cash generation.
The ratio gyrates between negative and strongly positive values, largely because net income is distorted by non-operating items and lumpy milestone or royalty recognition, as the Q3 2025 net income of $117.3M against operating cash flow of just $13.1M illustrates. This pattern suggests reported profitability should be treated with caution until cash conversion stabilizes across several consecutive quarters. Investors should monitor whether operating cash flow catches up to earnings over a longer window.
Free Cash Flow Turns Negative Recently
Per reported figures, LGND's free cash flow margin moved from 93.7% in Q1 2026 to -35.2% in Q3 2026, with free cash flow of -$27.7M in the most recent quarter after a $48.5M result in the prior quarter.
The swing reflects the volatility of royalty timing and working capital movements rather than a steady underlying cash trajectory, with working capital changes of -$47.6M in Q3 2026 weighing heavily on the period. Because capital expenditure is minimal, the free cash flow profile is driven almost entirely by operating cash timing, making single-quarter readings poor indicators of run-rate. Management's ability to sustain positive free cash flow across quarters warrants further investigation.
Cash Deployed Toward Acquisitions and Buybacks
As reported in the financial statements, LGND recorded a net acquisition outflow of $836.3M in Q3 2026 and share repurchases of $60.0M in Q2 2026, while paying no dividends across the period.
The scale of the Q3 2026 acquisition outflow relative to quarterly operating cash flow indicates the company is funding growth through balance sheet capacity rather than internally generated cash. The absence of dividends alongside repurchases suggests capital is being prioritized for royalty acquisitions and selective buybacks. Investors should assess whether acquired royalty streams generate returns sufficient to justify the deployed capital, given the reported cash volatility.
Stock Compensation Masks Cash Cost
Based on the supplied data, stock-based compensation of $18.2M in Q3 2026 and $13.7M in Q2 2026 represents a non-cash add-back that flatters operating cash flow while still diluting shareholders.
Because stock-based compensation is added back to arrive at operating cash flow, the reported cash generation overstates the economic cost of running the platform, relative to the quarterly operating income of $8.6M in Q2 2026. This implies that the true cash-equivalent earnings power may be lower than headline cash flow suggests. Investors may wish to evaluate free cash flow after treating equity compensation as a real expense.